论文部分内容阅读
(http://www.cancer.gov/clinicaltrials/results/head-and-neck) 1.Cetuximab (Erbitux) Plus Chemo Extends Survival in Advanced Head and Neck Cancer (Posted: 06/26/2007)-Patients with recurrent or metastatic squamous cell carcinoma of the head and neck who received cetuximab (Erbitux) in addition to standard chemotherapy lived about three months longer than those receiving
(http://www.cancer.gov/clinicaltrials/results/head-and-neck) 1. Cetuximab (Erbitux®) Plus Chemo Extends Survival in Advanced Head and Neck Cancer (Posted: 06/26/2007) -Patients with recurrent or metastatic squamous cell carcinoma of the head and neck who received cetuximab (Erbitux) in addition to standard chemotherapy lived about three months longer than those receiving